IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Takeda an nounced that it was in te grat ing its two wholly-owned agro chemi cal sub sid iar ies, Tohoku
Takeda Kasei Chem i cals and Takeda Agro. As of April 1, they formed the new com pany Takeda Agro Man -
u fac tur ing.
• Year: 1998
Takeda an nounced plans to ex pand its clin i cal test ing op er a tions in the US. It al ready has two R&D bases
in the coun try through its joint ven ture with Abbott (USA), TAP, and Takeda Amer ica R&D Cen ter, a
wholly-owned subsidiary.
Takeda Eu rope Hold ings, a wholly owned sub sid iary of Takeda, es tab lished its own de vel op ment unit,
Takeda Eu rope R&D Cen ter, in Lon don. Takeda planned to close its R&D cen ter in Frank furt, Ger many.
The new en tity will be re spon si ble for over see ing Eu ro pean de vel op ment of Takeda’s new drugs and im -
prov ing the ef fi ciency of the R&D process.
Takeda Pharma GmbH (Ger many), the 50:50 jv with Gruenenthal (Ger many), es tab lished a
wholly-owned sub sid iary, Takeda Pharma AG (Swit zer land).
Takeda an nounced plans to es tab lish an in de pend ent, wholly owned phar ma ceu ti cal mar ket ing com pany
in the US, Takeda Pharmaceuticals Amer ica. It will be cap i tal ized at $100 mil lion, and mar ket Actos
(pioglitazone) in con junc tion with Lilly (USA), as well as co-pro mote se lected Lilly insulin products.
Takeda an nounced a pro posal to change com pany rules to al low it to buy back up to 80 mil lion of its is -
sued shares.
The Jap a nese au thor i ties told Takeda to halt man u fac tur ing and sale of Avan (idebenone), a ce re bral me -
tab o lism improver. A num ber of sim i lar prod ucts from other man u fac tur ers were also delisted. Orig i nally
ap proved in the 1980s for the im prove ment of brain me tab o lism in pa tients who had suf fered a stroke or
hem or rhage, they were later ap proved for use in con di tions such as se nile de men tia. Re-eval u a tion of
these drugs showed them to be in ef fec tive. An a lysts noted that sales of these prod ucts had been fall ing
and that the withdrawal would simply accelerate the process.
Takeda Italia ac quired a man u fac tur ing plant in Cerano, It aly from Societa Prodotti Antibiotici (SPA).
Takeda es tab lished Takeda Eu rope Hold ings in Lon don. This fol lowed the 1997 es tab lish ment of Takeda
Amer ica Hold ings in the US. The es tab lish ment of these two com pa nies was aimed at help ing Takeda ac -
cel er ate its in de pend ent busi ness de vel op ment over seas. The new com pany (which has cap i tal of
STG60.7 mil lion) was es tab lished by in vest ing shares of Takeda’s five ex ist ing Eu ro pean subsidiaries and
jv companies in kind.
Takeda an nounced that its food and vi ta min di vi sion had merged with the bulk vi ta min pro duc tion sub -
sid iary Takeda Chem i cal Prod ucts USA and the mar ket ing sub sid iary Takeda USA to cre ate Takeda Vi ta -
min & Food USA.
• Year: 1997
The US De part ment of Jus tice be gan a probe of TAP’s mar ket ing of Lupron, for pros tate can cer. Takeda
es tab lished Takeda Amer ica Hold ings, cap i tal ized at $118 mil lion, which will man age all the US ac tiv i ties
of Takeda. TAP has es tab lished Takeda in the US to some ex tent, but not hav ing a ma jor ity share has ap -
par ently made draw ing up mar ket ing strat e gies dif fi cult. Takeda was also re ported to be plan ning a move
to quar terly set tle ment of ac counts and seek ing a list ing on the NYSE. Shoji Isahaya, Pres i dent of Takeda
Amer ica, be came Pres i dent of TAH. The com pany was cap i tal ized through stock trans ferred from TAP
Holdings and Takeda America R&D Center.
© 2009 IMS Health In cor po rated or its af fil i ates Page 119